Our company
CASC8 bvba was established in June 2016 by Prof. Dr. Marc Hendrikx
in Keerbergen (Belgium).
The team has over 70 years of combined experience in the field of cardiology, biomedical R&D, surgery and medicine as well as relevant commercial expertise.
Currently approximately €5,000,000 has been invested into the development of CASC technology with the help of CEO’s funds and VLAIO public funds.
This innovative technology has also been patented ( EU (EP2258833B1) )
Marc Hendrikx
Founder & CEO
Paul Celen
CFO
Dirk Groenewegen
CSO
Ellen Heeren
Cell Biologist
Our Mission
The mission of CASC8 is to develop a regenerative therapy for Heart Failure (HF), using autologous CASCs, reversing the decreased heart function by replacing the lost cardiac tissue.
Our Vision
The vision of CASC8 is to bring CASC technology from the current preclinical stage to application in the patient in everyday clinical practice, and develop other (cardiac or cell) therapies and bring them to the daily clinical practice.
Problems patients face today
1 / Current treatments
Treatment outcomes for people with heart failure are still unacceptable today.
2 / Statistics
1 in 3 patients with heart failure dies within one year of hospital admission.
3 / Treating symptoms, not the cause
Current therapies address physical symptoms but do not replace the viable cardiac tissue.
4 / Mental health
Heart failure significantly impacts a patient's health and wellbeing which can lead to social isolation, anxiety and depression.
Our Solution
CASC In Action
bipolar electromechanical mapping of a myocardial infarction as a consequence of temporary occlusion of the left anterior descending artery (LAD). Note the severely reduced voltages in the anterior wall of the heart.Wall motion in the anterior wall is impaired.
Two months after cardiac atrial stem cell transplantation in the infarcted area, bipolar voltages are restored to normal. Wall motion has recovered and left ventricular volumes restored to normal.